Premium
Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin‐2 activated killer cells and by activated monocytes
Author(s) -
Allavena P.,
Grandi M.,
D'Incalci M.,
Geri O.,
Giuliani F. C.,
Mantovani A.
Publication year - 1987
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910400119
Subject(s) - cytotoxicity , cytotoxic t cell , biology , effector , lymphokine activated killer cell , interleukin 2 , cell culture , cancer research , immunology , cell , drug resistance , in vitro , cytokine , interleukin 12 , genetics
Two human cell lines, the colon carcinoma Lovo and the transformed intestinal 1–407, and their variants (Lovo/Dx and l‐407/Dx), with pleiotropic resistance to cancer chemothera‐peutic drugs, were examined for their susceptibility to human lnterleukin‐2‐activated killer cells and to activated mono‐cytes. These non‐specific or broadly specific effector cells expressed cytotoxicity levels on pleiotropically resistant tumor cells comparable to those of the parental cell populations. This finding provides a rationale for immunological approaches designed to eradicate residual tumor cells surviving and resistant to cytotoxic chemotherapy.